1887

Abstract

Vaccinia-immune globulin (VIG) was used to treat severe complications of smallpox vaccination, but its use was controversial because it resolved disease in only some clinical cases. VIG is a pool of hyperimmune sera collected from individuals with a high neutralizing titre against the intracellular mature form (IMV) of vaccinia virus (VACV), but activity against the extracellular enveloped form (EEV) was often not considered. Here, the efficacy of anti-VACV antibodies (Abs) in protecting mice from intranasal infection with the VACV strain Western Reserve (WR) was evaluated. Mice were immunized passively with hyperimmune rabbit Abs (IgG) generated against inactivated IMV or produced following infection by VACV; subsequently, animals were challenged with VACV WR. The results demonstrated that: (i) good protection requires Abs to EEV in addition to IMV; (ii) Abs were effective when given before or up to 4 days after infection; and (iii) protection of mice from VACV WR correlated with a reduction of virus replication in lungs, but not in brain. In agreement with studies conducted before smallpox was eradicated and recent studies using EEV antigens for immunization, this study reiterates the importance of anti-EEV Abs in protecting against orthopoxvirus infection and illustrates the need to evaluate both anti-IMV and anti-EEV neutralizing Abs in VIG.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80660-0
2005-04-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/4/vir860991.html?itemId=/content/journal/jgv/10.1099/vir.0.80660-0&mimeType=html&fmt=ahah

References

  1. Alcami, A. & Smith, G. L. ( 1992; ). A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71, 153–167.[CrossRef]
    [Google Scholar]
  2. Anderson, S. G. & Skegg, J. ( 1970; ). The international standard for anti-smallpox serum. Bull W H O 42, 515–523.
    [Google Scholar]
  3. Appleyard, G. & Andrews, C. ( 1974; ). Neutralizing activities of antisera to poxvirus soluble antigens. J Gen Virol 23, 197–200.[CrossRef]
    [Google Scholar]
  4. Appleyard, G., Hapel, A. J. & Boulter, E. A. ( 1971; ). An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol 13, 9–17.[CrossRef]
    [Google Scholar]
  5. Bedson, H. S. & Duckworth, M. J. ( 1963; ). Rabbit pox: an experimental study of the pathways of infection in rabbits. J Pathol Bacteriol 85, 1–20.[CrossRef]
    [Google Scholar]
  6. Bell, E., Shamim, M., Whitbeck, J. C., Sfyroera, G., Lambris, J. D. & Isaacs, S. N. ( 2004; ). Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology 325, 425–431.[CrossRef]
    [Google Scholar]
  7. Belyakov, I. M., Earl, P., Dzutsev, A. & 8 other authors ( 2003; ). Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 100, 9458–9463.[CrossRef]
    [Google Scholar]
  8. Boulter, E. A. ( 1969; ). Protection against poxviruses. Proc R Soc Med 62, 295–297.
    [Google Scholar]
  9. Boulter, E. A. & Appleyard, G. ( 1973; ). Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol 16, 86–108.
    [Google Scholar]
  10. Boulter, E. A., Zwartouw, H. T., Titmuss, D. H. & Maber, H. B. ( 1971; ). The nature of the immune state produced by inactivated vaccinia virus in rabbits. Am J Epidemiol 94, 612–620.
    [Google Scholar]
  11. Bray, M. & Wright, M. E. ( 2003; ). Progressive vaccinia. Clin Infect Dis 36, 766–774.[CrossRef]
    [Google Scholar]
  12. Earl, P. L., Americo, J. L., Wyatt, L. S. & 15 other authors ( 2004; ). Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 428, 182–185.[CrossRef]
    [Google Scholar]
  13. Fenner, F., Henderson, D. A., Arita, I., Jezek, Z. & Ladnyi, I. D. ( 1988; ). Smallpox and its Eradication. Geneva: World Health Organization.
  14. Fenner, F., Wittek, R. & Dumbell, K. R. ( 1989; ). The Orthopoxviruses. London: Academic Press.
  15. Fogg, C., Lustig, S., Whitbeck, J. C., Eisenberg, R. J., Cohen, G. H. & Moss, B. ( 2004; ). Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 78, 10230–10237.[CrossRef]
    [Google Scholar]
  16. Galmiche, M. C., Goenaga, J., Wittek, R. & Rindisbacher, L. ( 1999; ). Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254, 71–80.[CrossRef]
    [Google Scholar]
  17. Gitlin, J. D., Gitlin, J. I. & Gitlin, D. ( 1976; ). Selective transfer of plasma proteins across mammary gland in lactacting mouse. Am J Physiol 230, 1594–1602.
    [Google Scholar]
  18. Hanson, C. V., Riggs, J. L. & Lennette, E. H. ( 1978; ). Photochemical inactivation of DNA and RNA viruses by psoralen derivatives. J Gen Virol 40, 345–358.[CrossRef]
    [Google Scholar]
  19. Hooper, J. W., Custer, D. M., Schmaljohn, C. S. & Schmaljohn, A. L. ( 2000; ). DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266, 329–339.[CrossRef]
    [Google Scholar]
  20. Hooper, J. W., Custer, D. M. & Thompson, E. ( 2003; ). Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306, 181–195.[CrossRef]
    [Google Scholar]
  21. Hooper, J. W., Thompson, E., Wilhelmsen, C., Zimmerman, M., Ichou, M. A., Steffen, S. E., Schmaljohn, C. S., Schmaljohn, A. L. & Jahrling, P. B. ( 2004; ). Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 78, 4433–4443.[CrossRef]
    [Google Scholar]
  22. Hopkins, R. J. & Lane, J. M. ( 2004; ). Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis 39, 819–826.[CrossRef]
    [Google Scholar]
  23. Hopkins, R. J., Kramer, W. G., Blackwelder, W. C., Ashtekar, M., Hague, L., Winker-La Roche, S. D., Berezuk, G., Smith, D. & Leese, P. T. ( 2004; ). Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers. Clin Infect Dis 39, 759–766.[CrossRef]
    [Google Scholar]
  24. Kaplan, C. ( 1962; ). A non-infectious smallpox vaccine. Lancet ii, 1027–1028.
    [Google Scholar]
  25. Kaplan, C., Benson, P. F. & Butler, N. R. ( 1965; ). Immunogenicity of ultraviolet-irradiated, non-infectious, vaccinia-virus vaccine in infants and young children. Lancet i, 573–574.
    [Google Scholar]
  26. Kempe, C. H. ( 1960; ). Studies smallpox and complications of smallpox vaccination. Pediatrics 26, 176–189.
    [Google Scholar]
  27. Kempe, C. H., Berge, T. O. & England, B. ( 1956; ). Hyperimmune vaccinal gamma globulin; source, evaluation, and use in prophylaxis and therapy. Pediatrics 18, 177–188.
    [Google Scholar]
  28. Law, M. & Smith, G. L. ( 2001; ). Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280, 132–142.[CrossRef]
    [Google Scholar]
  29. Law, M. & Smith, G. L. ( 2004; ). Studying the binding and entry of the intracellular and extracellular enveloped forms of vaccinia virus. Methods Mol Biol 269, 187–204.
    [Google Scholar]
  30. Madeley, C. R. ( 1968; ). The immunogenicity of heat-inactivated vaccinia virus in rabbits. J Hyg (Lond) 66, 89–107.[CrossRef]
    [Google Scholar]
  31. Moss, B. ( 2001; ). Poxviridae: the viruses and their replication. In Fields Virology, 4th edn, pp. 2849–2883. Edited by D. M. Knipe & P. M. Howley. Philadelphia, PA: Lippincott-Raven.
  32. O'Callaghan, C. A., Byford, M. F., Wyer, J. R., Willcox, B. E., Jakobsen, B. K., McMichael, A. J. & Bell, J. I. ( 1999; ). BirA enzyme: production and application in the study of membrane receptor–ligand interactions by site-specific biotinylation. Anal Biochem 266, 9–15.[CrossRef]
    [Google Scholar]
  33. Payne, L. G. ( 1980; ). Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol 50, 89–100.[CrossRef]
    [Google Scholar]
  34. Pütz, M. M., Ammerlaan, W., Schneider, F., Jung, G. & Muller, C. P. ( 2004; ). Humoral immune responses to a protective peptide-conjugate against measles after different prime-boost regimens. Vaccine 22, 4173–4182.[CrossRef]
    [Google Scholar]
  35. Ramírez, J. C., Tapia, E. & Esteban, M. ( 2002; ). Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol 83, 1059–1067.
    [Google Scholar]
  36. Schriewer, J., Buller, R. M. L. & Owens, G. ( 2004; ). Mouse models for studying orthopoxvirus respiratory infections. Methods Mol Biol 269, 289–308.
    [Google Scholar]
  37. Smith, G. L. & Law, M. ( 2004; ). The exit of vaccinia virus from infected cells. Virus Res 106, 189–197.[CrossRef]
    [Google Scholar]
  38. Smith, G. L., Vanderplasschen, A. & Law, M. ( 2002; ). The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 83, 2915–2931.
    [Google Scholar]
  39. Thorne, C. D., Hirshon, J. M., Himes, C. D. & McDiarmid, M. A. ( 2003; ). Emergency medicine tools to manage smallpox (vaccinia) vaccination complications: clinical practice guideline and policies and procedures. Ann Emerg Med 42, 665–680.[CrossRef]
    [Google Scholar]
  40. Tscharke, D. C., Reading, P. C. & Smith, G. L. ( 2002; ). Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 83, 1977–1986.
    [Google Scholar]
  41. Turner, G. S. ( 1967; ). Respiratory infection of mice with vaccinia virus. J Gen Virol 1, 399–402.[CrossRef]
    [Google Scholar]
  42. Turner, G. S. & Squires, E. J. ( 1971; ). Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. J Gen Virol 13, 19–25.[CrossRef]
    [Google Scholar]
  43. Williamson, J. D., Reith, R. W., Jeffrey, L. J., Arrand, J. R. & Mackett, M. ( 1990; ). Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 71, 2761–2767.[CrossRef]
    [Google Scholar]
  44. Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. ( 2004; ). Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci U S A 101, 4590–4595.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80660-0
Loading
/content/journal/jgv/10.1099/vir.0.80660-0
Loading

Data & Media loading...

Supplements

vol. , part 4, pp. 991 – 1000

Weight change and SOI of sacrificed animals, shown in Fig. 6 of the paper

Virus spread in the presence of Ab

[Single PDF file](176 KB)



PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error